During mammalian development, specific cells within the mesoderm differentiate into pluripotent hematopoietic stem cells that form all blood cell types, including lymphocytes, megakaryocytes, erythrocytes, granulocytes, and monocytes. Proto-oncogenes have been implicated in the regulation of cellular differentiation. Several mammalian proto-oncogenes exhibit restricted patterns of expression, suggesting that their transcription is tightly controlled and that they encode proteins with lineage-specific functions (30, 33, 38) . The c-fps/fes (herein referred to as c-fes) proto-oncogene encodes a 92-kDa cytoplasmic protein-tyrosine kinase that includes a Src homology 2 domain and a carboxyl-terminal catalytic domain (29) . c-fes is distinct from members of the Src family of tyrosine kinases in that it lacks a negative regulatory tyrosine phosphorylation site in its carboxyl-terminal region, is not modified by N-terminal myristylation, and does not have a Src homology 3 domain. Previously, the c-fes protein (p92 c-fes ) had been detected only in hematopoietic cells in adult mammals and birds, predominantly in differentiated neutrophils and macrophages and their precursors (7, 17, 19, 29, 32) . However, more recent experiments have shown that c-fes is also expressed in vascular endothelial cells and several rapidly proliferating embryonic tissues (3, 10) .
A requirement for p92 c-fes in myeloid-cell (monocyte and neutrophil) development has been suggested by a number of experiments. Introduction of a c-fes genomic clone into leukemic (K562) cells induces them to undergo terminal myeloid differentiation (40) . c-fes kinase activity increases following treatment of HL60 cells with the granulocyte inducer retinoic acid and monocyte inducers such as 1,25-dihydroxyvitamin D 3 (32, 39) . Furthermore, inhibition of c-fes expression with antisense oligonucleotides in HL60 cells before induction with retinoic acid leads to the activation of programmed cell death (8, 20) . Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 are potent hematopoietic growth factors which stimulate the proliferation and differentiation of various hematopoietic cells, including granulocyte and macrophage progenitor cells. One study reported a direct association between p92 c-fes and the common ␤ chain of the human interleukin-3 and GM-CSF receptors that is catalytically activated upon ligand binding (13) . These observations suggest that p92 c-fes is involved in regulating proliferation and differentiation during myelopoiesis. It may also be essential for the survival of myeloid cells during differentiation.
A 13-kilobase-pair (kb) c-fes human genomic construct is expressed in transgenic mice in a tissue-specific manner and at levels comparable to that of the endogenous murine gene (11) . Furthermore, expression of the human transgene in mouse bone marrow is independent of the integration site and proportional to the transgene copy number. Remarkably, this 13-kb genomic fragment includes only 446 bp of 5Ј-and 1.4 kb of 3Ј-flanking sequences and must, by definition, include all cis-acting DNA elements required for high levels of myeloidcell-specific expression. To locate where these cis-acting elements reside and to identify trans-acting factors which bind to them, we have studied the expression of various c-fes DNA elements linked to a reporter gene in transient-transfection assays in two myeloid cell lines. We report that the 5Ј-flanking 151 bp of c-fes contain a strong myeloid-cell-specific promoter. This promoter contains functionally important binding sites for Sp1, PU.1, and a novel transcription factor. Also, PU.1 transactivates the promoter in nonmyeloid cell lines.
MATERIALS AND METHODS
RNase protection assay. Total RNA was isolated from the following humanderived cell lines: HeLa, Jurkat, K562, U937, HL60, and THP-1. In addition, a separate flask of U937 cells was treated with phorbol 12-myristate 13-acetate (PMA) at 54 nM for 16 h prior to RNA isolation. All cell lines were passaged 1:3 24 h prior to RNA extraction to ensure that cells were healthy. The TRIzol reagent (Gibco/BRL) for RNA purification was used as specified by the manufacturer except that two rounds of extraction were performed to completely remove contaminating genomic DNA.
Antisense c-fes and ␤-actin RNA probes were generated by in vitro transcription with T7 polymerase and linearized plasmids. The c-fes probe corresponds to genomic DNA positions 11273 through 11645 (GenBank accession number X06292) and protects 273 bp of exon 19. The ␤-actin construct (Ambion) produces a 189-bp transcript and protects a 127-bp fragment. Analysis was performed as recommended by the manufacturer.
Plasmid construction. Plasmid pSVBR91 contains the 13-kb EcoRI human c-fes genomic locus and was kindly provided by A. J. M. Roebroek. Plasmid p446 contains the c-fes promoter (bp Ϫ446 to ϩ71) cloned upstream of the firefly luciferase reporter pGL2-basic (Promega). The 517-bp EcoRI-KpnI fragment from pSVBR91 was subcloned into SmaI-KpnI-digested pGL2. A series of 5Ј deletions were made by subcloning a BssHII-KpnI fragment (yielding p366), an EagI-KpnI fragment (yielding p151), and a SmaI-KpnI fragment (yielding p51) into pGL2. The p251 and p99 constructs were generated by subcloning PCRamplified products into pGL2-basic. Site-directed mutagenesis was performed with the following oligonucleotides: for PU.1, 5Ј-GGGGCCTGGGCCAACTGA AACCGCGGGAGCACCGGGCGCGGAATCAGGAACTGGCCGGGG TCCGCACCGGGCCTGAGTCGGTCCGGTAC-3Ј, and for FP4-3Ј, 5Ј-GGAG GAAGCGCGCCACCAGGAACTGGCC-3Ј. The underlined sequences indicate the nucleotides that were changed from wild-type sequences. A plasmid containing a mutation in the putative Ets site was made by first subcloning a construct harboring an Ets site mutation in 51 bp of 5Ј-flanking sequences and then cloning an EcoRI-SmaI partial restriction fragment upstream. Mutations in the potential AP-1 site were generated by PCRs with mutant primers. Constructs containing downstream sequences were generated by subcloning six distinct SacI fragments into the pGL2 promoter plasmid that contains a simian virus 40 (SV40) promoter 5Ј of the luciferase gene or four distinct BamHI fragments into a 3Ј site of p446. A 1.4-kb NsiI-EcoRI fragment from the c-fes genomic construct which contains 3Ј-flanking sequences was subcloned into both the pGL2 promoter and p446. Reference plasmids for transient transfections consisted of luciferase coding sequences with the Rous sarcoma virus promoter and growth hormone (GH) with the cytomegalovirus promoter. All plasmids were verified by dideoxy-DNA sequencing.
Cell culture and transient-expression analysis. Both U937 and K562 cells were grown in RPMI medium supplemented with 10% fetal bovine serum, penicillin, streptomycin, and glutamine. Cos and HeLa cells were grown in Dulbecco modified Eagle medium containing the same additives. Approximately 24 h prior to electroporation, the cells were split 1:3 with fresh medium. The following day, U937 and K562 cells were electroporated as described previously (22) . Cos and HeLa cells were transfected with Lipofectin reagent (Gibco/BRL). Duplicate transfections were performed by combining the cells, 100 g of luciferase reporter plasmid, and 2 g of the GH reference plasmid, pcDNA-GH, in electroporation cuvettes. At the time of plating, all of the U937 cells were stimulated with 54 nM PMA to increase the transfection efficiency as reported previously (22) . Cos cells were cotransfected with 16 g of pcDNA3 expression plasmid (Invitrogen) containing PU.1 or Elf-1, 4 g of test luciferase reporter plasmid, and 2 g of the GH reference plasmid. After 13 h (for U937 and K562 cells) or 48 h (for Cos and HeLa cells) of culture at 37ЊC, cells were harvested and assayed for protein content, secreted GH, and luciferase activity. Luciferase assays were performed with equivalent amounts of protein obtained from all cell extracts. GH activity was measured on transfected-cell medium supernatants by radioimmunoassay as specified by Nichols Institute. As a control for transfection efficiency, plasmid expression was quantitated as relative light units normalized to nanograms of GH secreted. All transfections were performed at least three times to ensure reproducibility.
Nuclear extracts and EMSAs. Nuclear extracts of U937 cells were prepared as described previously (5), assayed for protein content (Bio-Rad), and used to identify protein binding sites in the 5Ј region of the c-fes gene between positions Ϫ446 and ϩ71 relative to the primary transcriptional start site. Because of its length, this fragment was digested with EagI (which cuts at Ϫ151), thus generating two probes containing 294 and 223 bp of DNA. DNase I footprinting assays were performed essentially as described in reference 6.
Electrophoretic mobility shift assays (EMSAs) were performed by incubating 10 g of nuclear extract (2) with 10,000 dpm of each radiolabeled probe as described previously (14) . Alternatively, radiolabeled oligonucleotide probes were incubated with in vitro-translated proteins prepared with T7-coupled reticulocyte lysates (Promega). Reactions were performed for 15 min at 4ЊC or 30 min at room temperature.
The following oligonucleotides were utilized: c-fes Sp1 (Ϫ102 to Ϫ46), 5Ј-agc tTCGGGACGGTCGGGCCGGTCCCGCCCGCCCCTTCCCCTCCACAGGC CCGCCCCGGGG-3Ј; Sp1 consensus, 5Ј-gatcCCTGGCTAAAGGGGCGGG GCTTGGCCAGCC-3Ј; PU.1/Elf-1 binding site, PU.1 (Ϫ32 to Ϫ1), 5Ј-gatcAAA CCGCGGGAGGAGGAAGCGCGGAATCAGGA-3Ј; PU.1/FP4-3Ј (Ϫ32 to ϩ14), 5Ј-agcttAAACCGCGGGAGGAGGAAGCGCGGAATCAGGAACTG GCCGGGGTCC-3Ј; and the PU.1 consensus from the SV40 promoter (26) . The mutated PU.1 site in the PU.1 oligonucleotide (Ϫ32 to Ϫ1) and the SV40 oligonucleotide are listed in Fig. 7 and 8 . The sequences utilized to analyze the flanking site binding requirements were made in the context of the c-fes oligonucleotide PU.1/FP4-3Ј (Ϫ32 to ϩ14) and are as follows: mutation 1 (mut1), 5Ј-gcttAAACCGCGGGAGGAGGAAGCGCGCCACCAGGAACTGGCCGG GGTCC C-3Ј; mut2, 5Ј-agcttAAACCCGGGAGGAGGAAGCGCGCCACGG GGAACTGGCCGGGGTCC-3Ј; and mut3, 5Ј-agcttAAACCGCGGGAGGAG GAAGCGCCCTAATTAAGGCTGGCCGGGGTCC-3Ј. The underlined sequences represent mutated bases. The lowercase letters indicate the sequences used for subcloning purposes. The consensus AP-1 site is from the metallothionein promoter (25) . The rabbit polyclonal antisera specific for human Sp1, murine PU.1, human pan-fos, and murine pan-jun were purchased from Santa Cruz Biotechnology, Inc. A second polyclonal antibody specific for full-length PU.1 was a gift of David Kabat. A monoclonal antibody specific for Elf-1 was the generous gift of Jeff Leiden. Supershift and/or blocking reactions were performed as described above for EMSAs.
RESULTS
c-fes is transcribed in human myeloid cell lines. In the human genome the 3Ј end of fur, a gene encoding a transmembrane protein with receptor-like features, is located approximately 1 kb upstream of the first exon of c-fes (27) . Of note, fur and c-fes are expressed in distinct tissues. The 13-kb human c-fes genomic fragment, which displays high levels of tissuespecific expression in transgenic mice, contains 446 bp of 5Ј-flanking sequences and 1.4 kb of 3Ј-flanking sequences. The c-fes locus includes 19 exons, one DNase I-hypersensitive site located 5Ј of the first exon, and two sites located between exons 3 and 4 ( Fig. 1A) (15) . Previous studies of p92 c-fes indicated that it is preferentially expressed in myeloid cells in adults. To confirm and extend these results, we analyzed the relative levels of c-fes expression in various human cell lines by RNase protection analyses (Fig. 1B) . RNA was isolated from four myeloid cell lines (K562, U937, HL60, and THP-1), an epithelial carcinoma cell line (HeLa), and a T-cell line (Jurkat). As shown in Fig. 1B , c-fes mRNA was detected in U937, HL60, and THP-1 cells but was not detectable in either the T cells or epithelial cells. K562 cells were established from a patient with chronic myelogenous leukemia and exhibit both erythrocytic and early monocytic characteristics (18) . Experiments involving gene transfer into K562 cells with the 13-kb c-fes human genomic clone resulted in high levels of c-fes mRNA and kinase activity and subsequent myeloid differentiation (40). We did not detect any endogenous c-fes mRNA in K562 cells by RNase protection assays (Fig. 1B ) but could detect low levels by reverse transcription-PCR (data not shown). c-fes mRNA and protein levels have also been reported to increase as monocytes and granulocytes mature. Treatment of U937 cells with phorbol esters induces terminal monocytic differentiation. Therefore, we stimulated U937 cells with PMA in order to test the hypothesis that this would induce c-fes transcription. However, PMA treatment for 16 h decreased mRNA levels in U937 cells (Fig. 1B) . The lower panel in Fig. 1B , showing hybridization to a ␤-actin probe, demonstrates that similar amounts of RNA were analyzed in each sample.
Functional domains within the c-fes gene. Transient transfections into myeloid cells by electroporation were conducted to identify cis-acting sites within the 13-kb c-fes locus. Initially, we transfected a luciferase reporter plasmid containing bases VOL. 16, 1996 REGULATION OF c-fes BY A NOVEL TRANSCRIPTION FACTOR 1677
Ϫ446 to ϩ71 of c-fes into U937 cells. This plasmid (called p446) increased luciferase activity 125,000 times over that of the plasmid pGL2-basic negative control, which is expressed at very low levels in U937 cells ( Fig. 2A ). The level of activity obtained with the c-fes p446 reporter plasmid was 25% of that obtained with the RSV-luciferase positive control plasmid ( Fig. 2A) .
The human c-fes promoter contains a CpG island and no TATA element; multiple transcription start sites have been determined by primer extension analysis of U937 and HL60 mRNA (1). c-fes transcripts initiate at multiple sites within exon 1, and the primary site corresponds to the first nucleotide of published cDNA sequences (1). One additional cap site is located at the 5Ј border of exon 2. To determine if the first intron serves as a second promoter, we linked DNA sequences from this region to luciferase coding sequences and transfected this construct into U937 cells. In contrast to the high levels of expression noted for the sequences 5Ј to exon 1, sequences within the first intron contain no transcriptional activity (data not shown). To determine if other positive, cis-acting elements for transient c-fes expression exist within the 13-kb human genomic locus (in particular the third intron, where two DNase I-hypersensitive sites are located), various SacI and BamHI DNA fragments spanning the locus were cloned into a pGL2 plasmid containing the SV40 promoter (pGL2 promoter) or p446 (the c-fes promoter). The 1.4-kb 3Ј region up to the EcoRI site indicated in Fig. 1A elevated transient expression threefold compared with either the pGL2 promoter or p446 (data not shown). Taken together, our results indicate that the strongest positive, cis-acting DNA elements identified by transient-transfection analyses lie within the first 446 bp 5Ј of the primary mRNA cap site. Although a weak 3Ј enhancer element was identified by our experiments, we focused on the 446-bp 5Ј-flanking region.
To further localize cis-acting elements in the 446-bp c-fes promoter, deletion analyses were performed. A schematic representation of the luciferase constructs tested by transfection is shown in Fig. 2B . DNA sequences located between nucleotides Ϫ446 and Ϫ366 were largely dispensable for transient expression, as luciferase activity in U937 cells dropped only 10% if these nucleotides were removed from the 5Ј end. Plasmid p251 (containing 251 bp of 5Ј sequences) retained 77% of promoter activity compared with p446. However, when the region between Ϫ251 and Ϫ151 was deleted, expression was reduced to 38%. Finally, deletion of bp Ϫ99 to Ϫ51 essentially decreased activity to less than 1% of that observed with p446 (Fig. 2B) . We conclude that two important functional domains of the c-fes promoter reside within nucleotides extending from Ϫ251 to Ϫ151 and from Ϫ99 to Ϫ51 upstream of the primary site of transcription initiation.
The c-fes genomic locus contains a myeloid-cell-specific promoter. The 13-kb human c-fes transgene is expressed in a tissue-specific manner in transgenic mice. To determine if the 446-bp c-fes 5Ј promoter was also myeloid cell specific, the luciferase reporter plasmid, p446, was transiently transfected into myeloid and nonmyeloid cells. As shown in Fig. 3A , The promoterless plasmid pGL2 produced low levels of luciferase activity in all four cell lines tested. p446 was expressed at high levels in two myeloid cell lines (K562 and U937) and was at least 100 times more active than in the nonmyeloid cells (Cos and HeLa). Furthermore, the 446-bp 5Ј-flanking region elevated luciferase activity 186-fold over pGL2 in K562 cells and 115,000-fold over pGL2 in U937 cells. These results differ significantly from the 3-fold stimulation observed in Cos cells (p446 versus pGL2) and the 1.3-fold stimulation seen in HeLa cells (Fig. 3A) . In addition, p446 was not active in the Jurkat T-cell line (data not shown). It is important to note that reference GH levels for K562, Cos, and HeLa cells were identical and that U937 cells gave values two-to threefold lower. These results demonstrate that the 5Ј sequences upstream of the c-fes transcription initiation site contain a promoter that is active in a myeloid-cell-specific fashion. Of note, we predicted that the c-fes promoter would be active in K562 cells even though they express low levels of the endogenous gene because the 13-kb c-fes transgene is active when introduced into this cell line. As stated previously, stable K562 transformants containing the transgene synthesize high levels of c-fes mRNA and protein and exhibit high levels of kinase activity (40) . As shown in the previous section, a plasmid containing 151 bp of 5Ј c-fes sequences linked to luciferase was less active in U937 cells than one containing 446 bp but still resulted in 40,000-fold-higher activity than pGL2. To learn if the 151-bp region is regulated in a myeloid-cell-specific pattern, p151 was transiently transfected into U937, K562, Cos, and 3T3 cells. As shown in Fig. 3B , p151 generated luciferase activity at levels 20-to 30-fold higher in K562 and U937 cells than in 3T3 and Cos cells and thereby retained tissue-specific expression.
Sp1 interacts with the c-fes promoter. To identify nuclear protein binding sites within the 446-bp c-fes promoter, DNase I footprinting analyses were performed with nuclear extracts prepared from U937 cells. Four nuclear protein binding sites were identified in these experiments, and the data are summarized in Fig. 4 . The first footprint (FP1) extends from bp Ϫ408 to Ϫ386 and does not contain a previously described consensus motif. The second nuclear protein binding site (FP2) extends from bp Ϫ293 to Ϫ254 and includes a consensus nuclear protein binding site for the transcription factor Sp1 (Ϫ293 to Ϫ285). Interestingly, neither of these two nuclear protein binding sites was absolutely required for the in vitro activity of the c-fes promoter (i.e., p251 retained 77% of full promoter activity) (Fig. 2B) . The third footprint (FP3) includes nucleotides Ϫ76 to Ϫ65 and contains one DNase I-hypersensitive site. This region, which is footprinted weakly compared with the other footprints, contains three potential nuclear protein binding sites for the ubiquitous transcription factor Sp1. Sp1 sites have been identified in several other transcriptional regulatory elements that are present in myeloid-cell-specific genes, including CD11b (21). The fourth nuclear protein binding site (FP4) extends from Ϫ34 to ϩ1 on the antisense strand and from Ϫ34 to ϩ3 on the sense strand and is also surrounded by several hypersensitive sites. This region contains a consensus Ets family member binding site (Ϫ21 to Ϫ11) and a nonconsensus AP-1 binding site (Ϫ10 to Ϫ3). Comparison of this sequence with other previously described Ets binding sites suggests that this motif can bind to either or both of the transcription factors Elf-1 and PU.1 but not to Ets-1 (35, 36) . In addition, as is the case for multiple other Ets binding sites (9, 34, 37) , this region is immediately adjacent to a nonconsensus AP-1 family member nuclear protein binding site (5Ј-TGATTCC-3Ј, nucleotides Ϫ10 to Ϫ3 on the opposite strand). VOL. 16, 1996 REGULATION OF c-fes BY A NOVEL TRANSCRIPTION FACTOR 1679
As shown by computer search analyses, there are three putative Sp1 binding sites in the core c-fes promoter. To determine if Sp1 interacts with the promoter, EMSAs were conducted with an oligonucleotide probe that includes these three putative Sp1 binding sites and extends from bp Ϫ93 to Ϫ46 (Fig. 5) . The first three lanes in Fig. 5A exhibit results obtained with nuclear extracts prepared from HeLa, U937, and K562 cells respectively. As expected, all three cell lines contained DNA binding activities for the ubiquitous Sp1 protein when incubated with this oligonucleotide probe. To test the specificity of binding, the assays that are shown in lanes 4 through 6 of Fig. 5 also contained various cold competitor DNAs. A 100-fold molar excess of the identical c-fes oligonucleotide effectively inhibited DNA binding (Fig. 5, lane 4 ). An unrelated oligonucleotide that includes a consensus Sp1 site (see Materials and Methods) also competed for this DNA-protein complex (Fig. 5, lane 5) . However, another unrelated oligonucleotide (PU.1) corresponding to 32 bp of the c-fes promoter (Ϫ32 to Ϫ1) that includes a PU.1/Elf-1 binding site did not compete for this binding activity (Fig. 5, lane 6) . Addition of an antibody against Sp1 caused a supershift of the DNA-protein complex in K562 cells (Fig. 5B, lane 2) . These results strongly suggest that transcription factor Sp1 binds in vitro to at least one of the three consensus Sp1 sites in this portion of the c-fes promoter.
The PU.1/Elf-1 and FP4-3 sites are required for c-fes promoter activity in myeloid cells. As shown in Fig. 2B , a construct containing 51 bp of 5Ј c-fes sequences was inactive in transient assays. However, a footprinted region (FP4, from Ϫ34 to ϩ3) was detected by DNase I protection analyses (Fig. 4) . We therefore tested specific mutations in this footprinted region in the context of the entire 446-bp promoter by transient transfections. Figure 6A shows that promoter activity in U937 cells is sharply reduced (by approximately 90%) if the PU.1/Elf-1 DNA binding site is changed from 5Ј-GAGGAGGAAGCG C-3Ј to 5Ј-GAGCACCGGGCGC-3Ј, a mutation that renders it incapable of binding PU.1 or Elf-1 (see Fig. 7A ). In addition, a mutation in the flanking site FP4-3Ј (which does not affect PU.1 DNA binding activity) from 5Ј-TGATTCC-3Ј to 5Ј-TGG TGGC-3Ј resulted in an 80% decrease in expression compared with the wild-type construct (Fig. 6B) . Taken together, these data strongly suggest that important regulators for c-fes expression include Sp1 and PU.1 or Elf-1. In addition, either AP-1 or another DNA-binding protein(s) binding to FP4-3Ј also plays a role in the expression of c-fes in myeloid cells.
PU.1 and Elf-1 bind to the Ets site in the c-fes promoter, but AP-1 family members do not bind to FP4-3. DNase I footprinting experiments demonstrated the existence of a nuclear protein binding site within the c-fes promoter that could potentially bind both Ets and AP-1 family members. c-fes lacks a functional TATA box and has the sequence 5Ј-GAGGAGG VOL. 16, 1996 REGULATION OF c-fes BY A NOVEL TRANSCRIPTION FACTOR 1681 AAGC-3Ј at position Ϫ21 upstream of the transcription start site. Myeloid cells express the Ets family members Ets-1, Elf-1, and PU.1 (2b, 16) . Published DNA binding site specificities indicate that the c-fes promoter contains a consensus Elf-1 and/or PU.1 site: Ets-1 selectively binds 5Ј-CAGAGGATGT G-3Ј, while both Elf-1 and PU.1 bind the 5Ј-GAGGAGGAA GC-3Ј sequence (35, 36) . To determine if myeloid-cell nuclear extracts contain Ets binding activities that recognize this region of the c-fes promoter, EMSAs were performed. As shown in Fig. 7A , a radiolabeled oligonucleotide corresponding to bp Ϫ32 to Ϫ1 forms multiple nuclear protein complexes with extracts prepared from U937 cells. Three complexes evince specific interactions with the oligonucleotide probe because a 100-fold molar excess of unlabeled oligonucleotide competes for these DNA binding activities (Fig. 7A, lanes 1 and 2) . The fourth complex, is thought to be nonspecific, as an oligonucleotide with a mutation in the Ets site also competed for binding (Fig. 7A, lane 3) , as did a variety of oligonucleotides with dissimilar sequences (data not shown). We have determined that the most slowly migrating complex contains Elf-1, as it comigrates with in vitro-translated Elf-1 protein (Fig. 7A , lane 5) and is supershifted with a monoclonal antibody that specifically recognizes Elf-1 and not other Ets family members (Fig.  7A, lane 8) . In addition, a more rapidly migrating complex represents PU.1 binding to the Ets site, as it comigrates with in vitro-translated PU.1 (Fig. 7A, lane 4) and is blocked by the addition of anti-PU.1 antibody (Fig. 7A, lane 7) . Both antibodies used in these experiments were tested with pure Elf-1 and PU.1 proteins (see Fig. 8 ; also, data not shown). The fastestmigrating complex may represent a proteolytic product of PU.1 that retains DNA binding activity. However, it is not possible to unequivocally identify this protein, as it is not recognized by the antibody to PU.1.
To determine if AP-1 family members bind to the nonconsensus site at Ϫ10 to Ϫ3, a longer oligonucleotide which extended from Ϫ32 to ϩ14 (Ϫ32/ϩ14) and included FP4-3Ј was utilized. By using this oligonucleotide and unstimulated U937 nuclear extracts, six nuclear protein complexes were detected (Fig. 7B) . The upper two bands in Fig. 7B migrate very closely together and are resolved best in lane 3. Band three corresponds to an Elf-1 complex because it can be supershifted with an Elf-1-specific antibody (Fig. 7B, lane 9) . Similarly, bands five and six are identified as PU.1 by their ablation with the anti-PU.1 antibody, which now detects both intact and truncated PU.1 (Fig. 7B, lane 8) . To identify the proteolytic product of PU.1, binding reactions were modified and tested with antibodies that recognize the amino terminus (Santa Cruz) and full-length protein (from David Kabat, Oregon Health Sciences University). Bands five and six are also inhibited by competition with the PU.1 oligonucleotide (Ϫ32 to Ϫ1) (Fig.  7B, lane 3) . Therefore, in an investigation of the nonconsensus AP-1 site, bands one, two, and four were considered. Band two was not inhibited by cold oligonucleotide Ϫ32/ϩ14 and was therefore thought to be nonspecific (Fig. 7B, lane 2) . Neither band one nor band four was supershifted or reduced by antipan-fos or anti-pan-jun antibodies (Fig. 7B, lanes 6 and 7) . However, both of these antibodies affected specific AP-1-shifted bands detected in U937 cells treated with PMA by using a consensus metallothionein AP-1 probe (data not shown). Bands one and four were also not inhibited upon addition of a cold competitor consensus AP-1 oligonucleotide from the metallothionein promoter (Fig. 7B, lane 5) . We concluded that the diffuse band four corresponds to the nonspecific band indicated in Fig. 7A and that band one corresponds to a protein binding FP4-3Ј (see below). We also concluded that AP-1 does not regulate c-fes. PU.1 binds to the c-fes promoter at two sites, ؊21 to ؊14 and ؊8 to ؉3. A recent report (26) claims that in vitro-translated PU.1 binds to the sequence 5Ј-AATCAGGAACT-3Ј located at nucleotides Ϫ8 to ϩ3 of the c-fes promoter. The oligonucleotide Ϫ32/ϩ14 was used in EMSAs with in vitrotranslated PU.1. As shown in Fig. 8 , PU.1 binds to the PU.1/ FP4-3Ј (Ϫ32/ϩ14) oligonucleotide (lane 1) and is specifically inhibited by excess cold competitor (lane 2). Importantly, the PU.1 oligonucleotide (Ϫ32 to Ϫ1) also competes for binding (Fig. 8, lane 3) , while a mutation at the Ets site at Ϫ21 no longer competes (Fig. 8, lane 4) . This demonstrates that the Ϫ32/Ϫ1 oligonucleotide does not include the complete PU.1 site from Ϫ8 to ϩ3. Mutations 1, 2, and 3 of the flanking site FP4-3Ј (Ϫ8 to ϩ3) competed efficiently in our assays (Fig. 8,  lanes 8 to 10) , showing that the Ϫ21 site is intact. EMSAs with the Ϫ11/ϩ5 oligonucleotide also demonstrated binding of PU.1 in U937 nuclear extracts (see Fig. 10A, lane 1) . Because both the Ϫ32/Ϫ1 oligonucleotide (Fig. 7A ) and the Ϫ11/ϩ5 oligonucleotide (Fig. 10A) bind efficiently, we conclude that PU.1 binds to the Ets site at Ϫ21 and to the site at Ϫ8. The Ϫ32/ϩ14 oligonucleotide harbors two binding sites for PU.1 in addition to a site for the FP4-3Ј activity.
Transactivation of the myeloid-cell-specific c-fes promoter by PU.1. Given the specific binding of both Elf-1 and PU.1 to the c-fes promoter, we performed a series of transient-cotransfection experiments with both of these proteins in the nonmyeloid Cos cell line, which lacks endogenous Elf-1 or PU.1 activity. The promoterless luciferase expression vector pGL2, a minimal c-fes promoter construct (p51), and a c-fes promoter construct containing a mutation in the Ets site (p51m) were introduced into Cos cells with expression plasmids that produce high levels of Elf-1 or PU.1 driven by the cytomegalovirus promoter. As shown in Fig. 9 , cotransfection with PU.1 resulted in a reproducible fivefold stimulation of the c-fes promoter, and this stimulation was dependent on having the Ϫ21 Ets binding site intact. Similar results were obtained in experiments carried out with 3T3 cells (data not shown). Importantly, PU.1 transactivated constructs containing the full promoter (data not shown). In contrast, Elf-1 failed to transactivate the c-fes promoter in either cell line. On the basis of these results, we conclude that PU.1 is the most likely member of the Ets family of DNA-binding proteins to regulate c-fes gene expression. Furthermore, when the Ets site at position Ϫ21 is mutated, PU.1 fails to transactivate the c-fes promoter even though the PU.1 binding site at Ϫ8 is intact.
A novel factor binds to the FP4-3 site in the c-fes promoter. Our results clearly demonstrate that PU.1 binds specifically to the Ets site at nucleotide Ϫ21 of the c-fes promoter and that transactivation depends on the integrity of the Ϫ21 site. We performed EMSAs to determine what factor(s) binds to FP4-3Ј (Ϫ8 to ϩ3), having determined that AP-1 does not bind to FP4-3Ј (Fig. 7B) . These EMSAs utilized a shorter oligonucleotide probe (Ϫ11 to ϩ5) in order to isolate the FP4-3Ј binding interaction. Figure 10A shows the results of EMSAs performed to determine where the FP4-3Ј complex binds within the oligonucleotide Ϫ11/ϩ5. Lanes 1 through 5 of Fig. 10A demonstrate that the most slowly migrating complex corresponds to the FP4-3Ј binding activity. This band is inhibited by the wild-type oligonucleotide (Fig. 10A, lane 2) but not by any of the three mutations (Fig. 10A, lanes 3 through 5) . Importantly, a mutation in the FP4-3Ј site that affects the sequence 5Ј-GAATCAGGAACT-3Ј (mut1) interrupts binding and decreases c-fes expression in transient-transfection assays (Fig.  6B ). This mutation still allows PU.1 to bind to the Ϫ8 site. Lanes 6, 7, and 10 of Fig. 10A confirm that this FP4-3Ј-protein complex does not contain PU.1. Neither a consensus PU.1 oligonucleotide from SV40 nor a PU.1 antibody disrupts the FP4-3Ј complex. However, the SV40 PU.1 oligonucleotide specifically inhibits the PU.1 complex (the fastest two bands in Fig.  10A, lanes 6 and 7) . Furthermore, FP4-3Ј is not affected by Sp1 or AP-1 oligonucleotides or by antibodies to PU.1, Myb, Elf-1, Fos, or Jun (Fig. 10A, lanes 8 through 14) . VOL. 16, 1996 REGULATION OF c-fes BY A NOVEL TRANSCRIPTION FACTOR 1683 To determine the tissue distribution of the FP4-3Ј-binding factor, EMSAs were performed with nuclear extracts from myeloid (U937, THP-1, HL60, K562, and KG1) and nonmyeloid (HepG2, Jurkat, Clone 13, and HeLa) cell lines (Fig.  10B) . The FP4-3Ј-specific complex was present only in the nuclear extracts from the myeloid cell line, with the exception of HepG2 liver cells, which also contain the activity. The slowly migrating complex was not detected in Jurkat T-cell, Clone 13 B-cell, or HeLa epithelial-cell nuclear extracts. We conclude that the FP4-3Ј complex is largely restricted to myeloid cells.
DISCUSSION
The c-fes tyrosine kinase appears to be highly restricted in its pattern of expression in adult mammals. Although it is expressed in other tissues in murine and human embryos, after birth it is detected only in cells of the myeloid lineage (monocytes and neutrophils and their precursors) and in vascular endothelial cells. Several lines of evidence strongly implicate the c-fes protein as being crucial for monocytic and neutrophilic development: increased levels of kinase activity correlate with the maturation of monocytes and neutrophils (31, 38) , and inhibition of c-fes mRNA translation into protein leads to apoptotic death during neutrophilic differentiation (8, 20) . Re- markably, important cis-acting DNA elements that ensure high levels of c-fes transcription in myeloid cells must reside within a relatively short fragment of DNA: a 13-kb human transgene is expressed in the appropriate tissues at very high levels. The reasons for our interest in the c-fes gene are many. We want to learn which proteins are responsible for tightly controlling c-fes mRNA production. If c-fes kinase levels are critical for myeloid development, it stands to reason that the factors controlling its transcription will also be important in development. Also, a potent promoter for the myeloid lineage will be a useful tool for the generation of transgenic mice that inappropriately express gene products in these lineages. Given the extremely high levels of expression reported for a 13-kb human genomic fragment upon introduction into transgenic mice, we reasoned that it should be relatively important to identify cis-acting sites within this short region of genomic DNA.
We have demonstrated that promoter-proximal sequences from Ϫ151 to ϩ71 are sufficient to direct myeloid-cell-specific expression. The elements that appear to be the most important for activity during electroporation into U937 cells are located at nucleotides Ϫ99 to Ϫ51 and Ϫ34 to ϩ3. We have shown that the Ϫ99 region selectively binds the transcription factor Sp1. The footprinted site at Ϫ34 includes a consensus site for Ets family members PU.1 and/or Elf-1 as opposed to Ets-1. Although both PU.1 and Elf-1 recognize this site in in vitro binding reactions, PU.1 alone can transactivate the c-fes promoter in nonmyeloid cell lines (Cos and 3T3 cells), suggesting that PU.1 is the critical regulator of the c-fes promoter. Furthermore, macrophages that lack Elf-1 (because of gene targeting) still express normal levels of c-fes (2a). We have previously shown that mice deficient in PU.1 do not produce mature macrophages and neutrophils (31) . The blockage of macrophage and neutrophil development is coincident with c-fes expression in these lineages. We have isolated early myeloid cells lacking PU.1 and demonstrated a deficiency in c-fes expression (21a). Therefore, our genetic data are consistent with the transactivation results showing that PU.1 is the Ets family member that regulates c-fes.
PU.1 has been proposed as a regulator of other myeloidcell-specific genes, including CD11b (23), the M-CSF receptor (41) , and the macrophage scavenger receptor (37) . Interestingly, as is the case for CD11b and the M-CSF receptor, PU.1 binds to a site just 5Ј of the primary transcriptional start site in the c-fes promoter, which also lacks a consensus TATA box. Given the finding that PU.1 binds to TATA-binding protein in vitro (12) , it is tempting to speculate that PU.1 may function to recruit TFIID and then the other components of the basal transcriptional machinery to all three of these promoters.
The footprinted promoter-proximal region from Ϫ34 to ϩ3 also includes a weak consensus site for AP-1 family members that is directly adjacent to the Ets site. Many Ets family transcription factors interact with another protein when binding to DNA (4, 9, 34) . Combinatorial interactions between Ets-2 and AP-1 for the scavenger receptor promoter (37) and between Elf-1 and AP-1 for the GM-CSF promoter (34) have been described. PU.1 has been demonstrated to form a complex with the B-cell factor NF-EM5 to activate the immunoglobulin and 3Ј enhancers (24) . However, EMSAs performed with the PU.1 site in the c-fes promoter failed to detect PU.1 in a stable complex with another protein. A distinct assay for protein-DNA interactions (i.e., DNase I footprinting) clearly showed that both the PU.1 and FP4-3Ј sites bound nuclear proteins in U937 cells. Furthermore, both sites are functionally important for c-fes promoter activity in U937 cells. It seems possible that a PU.1/FP4-3Ј-protein interaction, while important to the regulation of c-fes expression, may not be sufficiently stable in a gel assay for detection. It is clear that the FP4-3Ј site (5Ј-GAATCAGGAACT-3Ј) does not bind either of the other myeloid transcription factors c-myb (5Ј-CAAC GG-3Ј) and CEBP/␣ (5Ј-GTGGAAAG-3Ј), as their consensus sites are distinct from FP4-3Ј (21) and FP4-3Ј does not bind antibodies specific for myb.
While this work was in progress, Ray-Gallet et al. reported that PU.1 binds to the c-fes promoter (26) . However, their analyses suggested that PU.1 binds to a site located at Ϫ8 to ϩ3 of the promoter. The oligonucleotide used for EMSAs in that report did not include the PU.1 site that we have identified and would therefore fail to detect PU.1 binding at bp Ϫ21 of the c-fes promoter. The Ϫ8 site overlaps the FP4-3Ј site, which is located at Ϫ9 to ϩ3 and for which we have demonstrated specific binding of a novel factor. Through our mutational analysis, we have identified a slowly migrating complex corresponding to a protein-DNA interaction at FP4-3Ј which is critical for promoter function (Fig. 10B ). This band is not supershifted or reduced by anti-PU.1 or by anti-Elf-1. We conclude that FP4 includes two binding sites for PU.1 in addition to FP4-3Ј. It is interesting that the Sp1, PU.1, and FP4-3Ј sites have been conserved in the chicken, feline, and human c-fes promoters. Finally, the FP4-3Ј complex appears to contain a DNA binding activity restricted in its expression to myeloid cells. It will be of interest to identify the factor(s) binding to FP4-3Ј that regulates c-fes in myeloid cells. Such a factor(s) could be useful for the further analysis of myeloid-cell-specific expression.
